Gandrup

• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Not authorised
  2022-502781-24-00 11 ASCVD - Atherosclerotic Cardiovascular Disease
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy … Pending
  2024-514388-24-00 4 Knee osteoarthritis
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• An efficacy and safety study of LTG-001 in osteoarthritis Pending
  2025-522755-26-01 4 Osteoarthritis of the knee
• An efficacy and safety study of LTG-321 in osteoarthritis Recruiting
  2026-525966-22-00 4 2026-06-24 Osteoarthritis of the knee
• A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Participants with Primary Knee … Recruiting
  2025-524668-39-00 4 2026-05-15 Knee Osteoarthritis
• AMAZE 1: A research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight Recruiting
  2024-520440-42-00 5 2026-05-07 Obesity
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting
  2024-513171-41-00 5 2025-09-11 Vitiligo
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
• Safety and Efficacy of AT-004 in Patients with Acne Vulgaris Ended recruitment
  2025-521510-25-00 4 2026-01-13 Acne vulgaris
• Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects with Alzheimer’s Disease (AD) Ended recruitment
  2024-519497-39-00 4 2025-10-03 Alzheimer's Disease
• Efficacy and Safety of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MA … Ended recruitment
  2024-515524-36-00 5 2025-05-30 Chronic Weight Management
• A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-336 as an Adjunct to Diet and Exercise in Ob … Ended recruitment
  2024-517264-27-00 4 2024-12-13 Obesity
• A multi-center, open-label extension study of subcutaneous secukinumab to evaluate the long-term safety and tolerability in polymyalgia rheu … Ended recruitment
  2023-508077-85-00 5 2024-11-19 Polymyalgia Rheumatica
• A Study on Diclofenac vs. Placebo for Knee Osteoarthritis Ended recruitment
  2024-510757-95-01 6 2024-08-01 Knee osteoarthritis
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended recruitment
  2023-505835-11-00 5 2021-03-12 Chronic Migraine
• A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended recruitment
  2023-505836-36-00 5 2021-03-12 Migraine
• ​​A scientific study on a vaccine against HPV infection (human papilloma virus) ​(a vaccine for the prevention of cervical cancer and genit … Ended recruitment
  2023-508683-30-00 5 2008-03-14 ​9vHPV vaccine is indicated in females ≥ 9 years of age in the prevent

Showing 1–24 of 34 trials